On May 21, Guardant Health rose 5.01% in regular trading, trading at $120.65/share, with trading volume of $106 million. The rally was driven by the announcement that the U.S. Food and Drug Administration has approved the company's Guardant360 Liquid CDx liquid biopsy test as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer.

The approved test integrates genomic and epigenomic profiling from a single blood draw, offering higher sensitivity to detect circulating tumor DNA. Notably, the Guardant360 Liquid CDx can assess a 100-times wider genomic footprint than the previously approved Guardant360 CDx, with results delivered within seven days. This approval significantly expands the commercial applicability of the platform across two major oncology indications.

Guardant Health is a precision oncology company headquartered in Palo Alto, California, offering blood and tissue tests, data sets, and analytics for cancer diagnosis and treatment selection.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)